Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WP1066 and Radiation Therapy in Newly Diagnosed Glioblastoma
NCT05879250Phase 2Recruiting
- Sponsor
- Northwestern University
- Start
- May 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of WP1066 in glioblastoma (GBM) (2 cohorts), sponsored by Northwestern University. Primary endpoints: Progression-Free Survival at 36 months and Tumor microenvironment activation and cluster interactions at 36 months. Started May 2024; status: recruiting.
02
Drugs
WP1066
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05879250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05879250.